A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T. J. van Bussel, Jan H.M. Schellens, Dorte Nielsen et al.|British Journal of Cancer|2020Cited by 127
EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLCNatalie I. Vokes, L.C. Villaruz, L. Paz-Ares et al.|Journal of Thoracic Oncology|2024Cited by 0